> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# HUTCHMED clears CMC rejection to win dual China approvals for SYK inhibitor sovleplenib
- URL: https://chinapharmadesk.com/hutchmed-sovleplenib-china-itp-waiha-approval/
- Published: 2026-11-19T14:55:29.000Z
- Updated: 2026-11-19T14:55:33.000Z
- Description: HUTCHMED (HKEX: 00013; NASDAQ: HCM) won simultaneous NMPA approvals (CXHS2600027, CXHS2600058) on Nov 19, 2026 for SYVIK (sovleplenib) in adult ITP and wAIHA 11 months after an impurity rejection.
- Author: Lin Yi
- Tags: Desk analysis, Pipeline, Autoimmune & Immunology, Regulation

[HUTCHMED (China) Limited](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1119/2026111900797.pdf?ref=chinapharmadesk.com) (`HKEX: 00013`; `NASDAQ/AIM: HCM`) announced on November 19, 2026 ([SEC Form 6-K Exhibit 99.2](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000080/hcm-ex99d2.htm?ref=chinapharmadesk.com)) that China’s National Medical Products Administration (`NMPA`) has granted simultaneous marketing approvals for two New Drug Applications of its oral spleen tyrosine kinase (`SYK`) inhibitor `SYVIK` (`sovleplenib` / `HMPL-523`, Chinese trade name `Saiweike`): adult chronic primary immune thrombocytopenia (`ITP`) after an insufficient response to at least one prior therapy (`CXHS2600027`), and adult warm antibody autoimmune hemolytic anemia (`wAIHA`) after an insufficient response to prior corticosteroid therapy (`CXHS2600058`). The dual clearance makes `sovleplenib` the first `SYK` inhibitor approved in China and the first oral targeted therapy cleared in the country for `wAIHA`—completing an 11-month regulatory recovery after a December 30, 2025 `NMPA` non-approval notice over manufacturing impurity thresholds stalled the original January 2024 `ITP` filing and prompted HUTCHMED to withdraw its U.S. and European Phase 1 `ITP` trial (`NCT06291415`).

While HUTCHMED retains 100% worldwide rights to `sovleplenib` and secured U.S. Food and Drug Administration (`FDA`) Orphan Drug Designations for `ITP` ([October 29, 2026](https://static.cninfo.com.cn/finalpage/2026-10-29/1225638682.PDF?ref=chinapharmadesk.com)) and `wAIHA` ([November 5, 2026](https://static.cninfo.com.cn/finalpage/2026-11-05/1225658575.PDF?ref=chinapharmadesk.com)), the simultaneous China approvals arrive six days after the November 14 publication of the [2026 National Reimbursement Drug List (NRDL)](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/), meaning `SYVIK` will launch in China as a self-pay and commercial-insurance product throughout 2027 ahead of the mid-2027 `NRDL` negotiation window.

## How a two-indication priority review recovered from the December 2025 impurity rejection

The regulatory trajectory of `sovleplenib` illustrates both the tightening of Chemistry, Manufacturing, and Controls (`CMC`) impurity standards at the `NMPA`’s Center for Drug Evaluation (`CDE`) and the speed of priority-review resubmissions once analytical and process controls are remediated:

- **Initial `ITP` filing and December 2025 `CMC` rejection (`CXHS2400006`)**: HUTCHMED submitted its first China NDA for `sovleplenib` in primary `ITP` on January 11, 2024 ([CNINFO filing 1218850747.PDF](https://static.cninfo.com.cn/finalpage/2024-01-11/1218850747.PDF?ref=chinapharmadesk.com)) under Priority Review, backed by the Phase 3 `ESLIM-01` trial (`NCT05029635`). After nearly 24 months of review, the `NMPA` issued a non-approval notice (`Yaopin Tongzhijian`) on December 30, 2025 because batch impurity limits did not meet tightened `CDE` specifications.
- **Nine-month resubmission-to-approval sprint (`CXHS2600027` & `CXHS2600058`)**: After completing `CMC` impurity-reduction work, HUTCHMED re-qualified for Priority Review on January 8, 2026 and resubmitted the `ITP` NDA (`CXHS2600027`) on February 10, 2026\. In parallel, following positive Phase 3 topline results in `wAIHA` (`ESLIM-02`, `NCT05535933`) announced on [January 7, 2026](https://static.cninfo.com.cn/finalpage/2026-01-07/1224924247.PDF?ref=chinapharmadesk.com) and Breakthrough Therapy Designation in March 2026, the `CDE` accepted the `wAIHA` NDA (`CXHS2600058`) with Priority Review on [April 29, 2026](https://static.cninfo.com.cn/finalpage/2026-04-29/1225266956.PDF?ref=chinapharmadesk.com). The `NMPA` cleared both applications together on November 19, 2026—9.3 months after the `ITP` refiling and 6.7 months after the `wAIHA` acceptance.

## Pivotal data across `ESLIM-01` (`ITP`) and `ESLIM-02` (`wAIHA`) against global FcRn, BTK, and SYK benchmarks

Both approved indications are anchored by randomized, double-blind, placebo-controlled Phase 3 trials in China (`300 mg` oral once daily for 24 weeks) published in *The Lancet Haematology* and presented at the European Hematology Association (`EHA`) 2026 Congress ([June 12, 2026 filing](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000039/hcm-20260612xex99d1.htm?ref=chinapharmadesk.com)):

| Trial / Indication                                                             | Design & Baseline Population                                                                                                           | Primary Endpoint (Durable Response)                                                                                      | Overall Response & Onset                                                                                                                                | Rescue Therapy & Key Subgroup Data                                                                                                                                                            | Grade ≥3 TEAEs & Discontinuations                                                                                                                 |
| ------------------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------- |
| **ESLIM-01** (NCT05029635 / CTR20211537) — **Adult Chronic Primary ITP**       | Randomized 2:1 (n = 188: 126 sovleplenib 300 mg QD vs. 62 placebo, 24 wks); median **4 prior lines**; **74.6%** had prior TPO / TPO-RA | **48.4% (61/126) vs. 0% (0/62)** (p < 0.0001, platelet count  ≥ 50 × 109/L on  ≥ 4 of 6 scheduled visits in Weeks 14–24) | Weeks 0–12 ORR: **68.3% vs. 14.5%**; Weeks 0–24 ORR: **70.6% vs. 16.1%** (p < 0.0001); median time to response **8 days** vs. 30 days                   | Prior  ≥ 4 lines DRR: **47.7% vs. 0%**; prior TPO/TPO-RA subgroup DRR: **46.8% vs. 0%** (p < 0.0001)                                                                                          | Grade  ≥ 3 TEAEs: **25.4% vs. 24.2%**; significant improvement in SF-36 physical function and fatigue (p < 0.05)                                  |
| **ESLIM-02** (NCT05535933 / CTR20221854) — **Adult Relapsed/Refractory wAIHA** | Randomized Phase 2/3 (Phase 3 double-blind 24 wks, 300 mg QD vs. placebo in post-glucocorticoid primary or secondary wAIHA)            | **66% vs. 15%** (p < 0.0001, durable hemoglobin response during Weeks 5–24)                                              | 24-week ORR (Hb ≥ 100 g/L with  ≥ 20 g/L increase from baseline without rescue): **70% vs. 22%** (p < 0.0001); median onset **3.1 weeks** vs. 6.3 weeks | Rescue therapy required: **16% vs. 54%**; RBC transfusion: **11% vs. 43%**; steroid/concomitant taper or stop: **50% vs. 15%** (p = 0.003); **prior rituximab DRR: 69% vs. 16%** (p = 0.0022) | Grade  ≥ 3 TEAEs: **43% vs. 59%** (most common: worsening wAIHA 18% vs. 43%, URI 2% vs. 11%); **0% treatment-related deaths or discontinuations** |

Placing `sovleplenib` against global and domestic hematology competitors highlights two distinct commercial dynamics:

1. **In `wAIHA`, `sovleplenib` captures an uncontested first-mover position in China**: Globally, the only other first-generation `SYK` inhibitor—Rigel Pharmaceuticals’ (`NASDAQ: RIGL`) `fostamatinib` (`Tavalisse`, approved by the U.S. FDA for `ITP` in 2018)—failed its Phase 3 `FORWARD` trial in `wAIHA` (`NCT03764618`) in June 2022 after an elevated placebo response in Eastern European sites and has never been approved in China. In the United States, Johnson & Johnson (`NYSE: JNJ`) won the first FDA targeted approval in `wAIHA` in August 2026 with its intravenous anti-`FcRn` antibody `nipocalimab` (`Imaavy`), while Sanofi (`EPA/NASDAQ: SNY`) is advancing its oral `BTK` inhibitor `rilzabrutinib` (`Wayrilz`, FDA-approved for `ITP` in August 2025) after reporting Phase 2b `LUMINA 2` `wAIHA` data in October 2026\. In China, where roughly 40,000 adults live with `wAIHA` and off-label rituximab, splenectomy, and chronic steroids remain the only options, `SYVIK` is the first approved targeted therapy of any class.
2. **In `ITP`, `sovleplenib` enters a crowded Chinese second-line market but targets the `TPO-RA`\-refractory pool**: According to `IQVIA` figures cited in HUTCHMED’s filings, China has roughly 430,000 prevalent `ITP` patients and 41,000 new diagnoses annually, with oral `TPO` receptor agonists—including Hengrui’s (`SSE: 600276`) `hetrombopag` (`Hengqu`), Novartis’s `eltrombopag` (`Revolade`), and Fosun Pharma’s `avatrombopag` (`Doptelet`)—plus Zai Lab / argenx’s anti-`FcRn` `efgartigimod` (`Vyvgart`) already entrenched in the basic `NRDL`. Meanwhile, InnoCare Pharma (`HKEX: 09969`; `SSE: 688428`) completed its China Phase 3 `ITP` trial for the `BTK` inhibitor `orelabrutinib` (`Yinuokai`, `NCT05124028`) and is preparing an sNDA. `Sovleplenib`’s clinical wedge in `ITP` is its `46.8%` durable response rate (versus `0%` on placebo) in the `74.6%` of `ESLIM-01` patients who had already failed `TPO/TPO-RA` therapy.

## Why HUTCHMED withdrew its U.S./EU `sovleplenib` trial and signaled a next-generation SYK NCE for out-licensing

For cross-border business development (`BD`) observers, the most consequential contrast lies between `sovleplenib`’s domestic commercial launch and its overseas clinical status.

On ClinicalTrials.gov, HUTCHMED’s multicenter U.S., German, Spanish, Norwegian, and Australian Phase 1 trial of `HMPL-523` in adult `ITP` (`NCT06291415`) is listed as **`WITHDRAWN` with `0` patients enrolled**. Because `sovleplenib` (`compound 225` in PCT patent `WO2012167733A1`) claims an earliest priority window from **2011–2012**, the 2024–2025 `CMC` delay in China compressed the remaining composition-of-matter patent runway outside China before global Phase 3 trials in `ITP` or `wAIHA` could even start.

Rather than funding late-stage Western trials on an aging patent clock, HUTCHMED CEO and CSO Weiguo Su, Ph.D., noted during recent investor briefings that the company can advance a **new chemical entity (`NCE`) next-generation `SYK` inhibitor with full patent life** into U.S. and global clinical development—using the clinical validation of `ESLIM-01` and `ESLIM-02` plus the October and November 2026 FDA Orphan Drug Designations (which confer 7-year U.S. orphan market exclusivity upon approval independently of composition-of-matter patents) to evaluate strategic partnering pathways alongside its emerging Antibody-Targeted Therapy Conjugate (`ATTC`) oncology platform (`HMPL-A251`, `HMPL-A580`, and `HMPL-A830`).

The next records that will determine `SYVIK`’s commercial trajectory and global value are initial provincial procurement (`guawang`) launch pricing in China across 300 mg tablet packs in Q1 2027; whether HUTCHMED prices `sovleplenib` for entry into the 2027 `NRDL` negotiation cycle (for effect January 1, 2028) across both `ITP` and `wAIHA` simultaneously; and whether the company files a U.S. IND or discloses an ex-China licensing agreement for either orphan-designated `sovleplenib` in `wAIHA` or a follow-on `SYK` new chemical entity in 2027.